{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T12:03:18Z","timestamp":1779624198765,"version":"3.53.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,24]]},"DOI":"10.7759\/cureus.109537","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T11:13:14Z","timestamp":1779621194000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Rituximab in Filipino Patients With Relapsing-Remitting Multiple Sclerosis: A Real-World Retrospective Cohort Study in a Resource-Limited Setting"],"prefix":"10.7759","author":[{"given":"Alyssa Pauline C","family":"Co","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fallen Grace E","family":"De la Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra T","family":"Aninang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma. Ericka S","family":"Del Mundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea Mae N","family":"Nobleza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig F","family":"Damian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0292","article-title":"Clinical presentation and diagnosis of multiple sclerosis","volume":"20","author":"Ford H","year":"2020","unstructured":"Ford H. Clinical presentation and diagnosis of multiple sclerosis. Clin Med (Lond). 2020, 20:380-3. 10.7861\/clinmed.2020-0292","journal-title":"Clin Med (Lond)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s44197-025-00353-6","article-title":"Epidemiology of multiple sclerosis: global, regional, national and sub-national-level estimates and future projections","volume":"15","author":"Khan G","year":"2025","unstructured":"Khan G, Hashim MJ. Epidemiology of multiple sclerosis: global, regional, national and sub-national-level estimates and future projections. J Epidemiol Glob Health. 2025, 15:21. 10.1007\/s44197-025-00353-6","journal-title":"J Epidemiol Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint18010002","article-title":"Multiple sclerosis: an ethnically diverse disease with worldwide equity challenges accessing care","volume":"18","author":"Rivera VM","year":"2025","unstructured":"Rivera VM. Multiple sclerosis: an ethnically diverse disease with worldwide equity challenges accessing care. Neurol Int. 2025, 18:10.3390\/neurolint18010002","journal-title":"Neurol Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2014.11.013","article-title":"Role of the blood-brain barrier in multiple sclerosis","volume":"45","author":"Ortiz GG","year":"2014","unstructured":"Ortiz GG, Pacheco-Mois\u00e9s FP, Mac\u00edas-Islas M\u00c1, et al.. Role of the blood-brain barrier in multiple sclerosis. Arch Med Res. 2014, 45:687-97. 10.1016\/j.arcmed.2014.11.013","journal-title":"Arch Med Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661882","article-title":"Rituximab in multiple sclerosis: are we ready for regulatory approval?","volume":"12","author":"Brancati S","year":"2021","unstructured":"Brancati S, Gozzo L, Longo L, Vitale DC, Drago F. Rituximab in multiple sclerosis: are we ready for regulatory approval?. Front Immunol. 2021, 12:661882. 10.3389\/fimmu.2021.661882","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)","volume":"33","author":"Kurtzke JF","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983, 33:1444-52. 10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"Meyer-Moock S","year":"2014","unstructured":"Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014, 14:58. 10.1186\/1471-2377-14-58","journal-title":"BMC Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.608491","article-title":"Deciphering multiple sclerosis progression","volume":"12","author":"Meca-Lallana V","year":"2021","unstructured":"Meca-Lallana V, Berenguer-Ruiz L, Carreres-Polo J, et al.. Deciphering multiple sclerosis progression. Front Neurol. 2021, 12:608491. 10.3389\/fneur.2021.608491","journal-title":"Front Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist M","year":"2018","unstructured":"Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018, 75:320-7. 10.1001\/jamaneurol.2017.4011","journal-title":"JAMA Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.2160","article-title":"Application of the 2017 revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated syndrome","volume":"75","author":"van der Vuurst de Vries RM","year":"2018","unstructured":"van der Vuurst de Vries RM, Mescheriakova JY, Wong YY, et al.. Application of the 2017 revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated syndrome. JAMA Neurol. 2018, 75:1392-8. 10.1001\/jamaneurol.2018.2160","journal-title":"JAMA Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari CG","year":"2022","unstructured":"Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2022, 269:159-83. 10.1007\/s00415-020-10362-z","journal-title":"J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Wallin M","year":"2019","unstructured":"Wallin M, Culpepper W, Nichols E, et. al. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2019, 18:269-85. 10.1016\/s1474-4422(18)30443-5","journal-title":"The Lancet Neurology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9084759","article-title":"Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study","volume":"2018","author":"Yamout BI","year":"2018","unstructured":"Yamout BI, El-Ayoubi NK, Nicolas J, El Kouzi Y, Khoury SJ, Zeineddine MM. Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study. J Immunol Res. 2018, 2018:9084759. 10.1155\/2018\/9084759","journal-title":"J Immunol Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25927","article-title":"Role of B cells in multiple sclerosis and related disorders","volume":"89","author":"Comi G","year":"2021","unstructured":"Comi G, Bar-Or A, Lassmann H, et al.. Role of B cells in multiple sclerosis and related disorders. Ann Neurol. 2021, 89:13-23. 10.1002\/ana.25927","journal-title":"Ann Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould A","year":"2024","unstructured":"Langer-Gould A, Li BH, Smith JB, Xu S. Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections. Neurol Neuroimmunol Neuroinflamm. 2024, 11:e200211. 10.1212\/NXI.0000000000200211","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00432","article-title":"Multiple sclerosis in the Asia Pacific region: a systematic review of a neglected neurological disease","volume":"9","author":"Cheong WL","year":"2018","unstructured":"Cheong WL, Mohan D, Warren N, Reidpath DD. Multiple sclerosis in the Asia Pacific region: a systematic review of a neglected neurological disease. Front Neurol. 2018, 9:432. 10.3389\/fneur.2018.00432","journal-title":"Front Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/489402-effectiveness-and-safety-of-rituximab-in-filipino-patients-with-relapsing-remitting-multiple-sclerosis-a-real-world-retrospective-cohort-study-in-a-resource-limited-setting","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T11:13:15Z","timestamp":1779621195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/489402-effectiveness-and-safety-of-rituximab-in-filipino-patients-with-relapsing-remitting-multiple-sclerosis-a-real-world-retrospective-cohort-study-in-a-resource-limited-setting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.109537","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,24]]}}}